×
Suggest this Article to:
TOP INDEXERS
Public Paper
-
verified
RESEARCH ADVANCES AIMED AT PROGNOSIS AND TREATMENT OF ALZHEIMERS DISEASE
ISSN: 2195 - 1381
Publisher: author
RESEARCH ADVANCES AIMED AT PROGNOSIS AND TREATMENT OF ALZHEIMERS DISEASE
View Paper PDF
Abstract
Alzheimer's disease (AD) continues to remain a public health concern especially for seniors globally. Increased life expectancy owing to improvement in medical advances may have increased AD's prevalence. It remains a matter of concern for stakeholders to look at progress made over the years and to fill the numerous gaps targeted at preventing the onset of AD and/or treating existing condition. In recent times, funding for AD research has increased in the United States (U.S) but the economic burden isn't left out. Controversies on gene modification still exists. The search for a definitive treatment still continues since recently approved drug-Aducanumab still has uncertainty concerning safety and efficacy. Newer therapies hold promise but we are still uncertain as we await their approval and real world evidence for safety and efficacy.
SUBMIT CONCEPT ASK QUESTION
International Category Code (ICC):
ICC-0202
Author: Godwin Okoye
International Journal Address (IPA):
IPA.ZONE/2195126641381
International Article Address (IAA):
IAA.ZONE/2195126641381
Paper Profile:
Private
Visitors: 0
Paper Evaluation: Pending
ASI-Factor: 0
Paper Improving: Pending
Paper Flaws: 0
References
1. Facts and figures. Alzheimer's Disease and Dementia. https://www.alz.org/alzheimersdementia/facts-figures? Accessed November 30, 2021.
2. 2021 alzheimer's disease facts and figures. Alzheimer's & Dementia. 2021;17(3):327-406. doi:10.1002/alz.12328
3. Grabher BJ. Effects of alzheimer disease on patients and their family. Journal of Nuclear Medicine Technology. 2018;46(4):335-340. doi:10.2967/jnmt.118.218057
4. Adi - dementia statistics. Alzheimer's Disease International (ADI). https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/. Accessed December 6, 2021.
5. Horovitz B. Alzheimer's deaths up 16 percent during COVID pandemic. AARP. https://www.aarp.org/health/brain-health/info-2021/alzheimers-dementia-coviddeaths.html. Published March 12, 2021. Accessed December 6, 2021.
6. Race, ethnicity, and alzheimer's. https://www.alz.org/aaic/downloads2020/2020_Race_and_Ethnicity_Fact_Sheet.pdf. Accessed November 30, 2021.
7. Economic burden of alzheimer disease and managed care considerations. The American Journal of Managed Care. 2020;26(Suppl 8). doi:10.37765/ajmc.2020.88482
8. Alzheimer's disease. Centers for Disease Control and Prevention. https://www.cdc.gov/dotw/alzheimers/index.html#:~:text=Alzheimer's%20disease%20is %20the%20most,of%20death%20for%20all%20adults. Published June 22, 2021. Accessed December 6, 2021.
9. The urgent need for alzheimer's research funding. Alzheimers.net. https://www.alzheimers.net/2013-09-25-alzheimers-research-funding. Accessed November 30, 2021.
10. New Study puts annual alzheimer's deaths on par with cancer. UsAgainstAlzheimer's. https://www.usagainstalzheimers.org/press/new-study-puts-annualalzheimer%E2%80%99s-deaths-parcancer#:~:text=The%20study's%20findings%20place%20Alzheimer's,Alzheimer's%20% 24550%20million%20in%20funding. Accessed December 6, 2021.
11. Increase in federal alzheimer's and dementia research funding, bold infrastructure for alzheimer's a. Alzheimer's Disease and Dementia. https://www.alz.org/news/2022/increase-in-federal-alzheimers-and-dementia-resear#:~:text=WASHINGTON%2C%20D.C.%2C%20March%2014%2C,as%20much%20as%20%243.5%20billion. Accessed May 24, 2022.
12. Cummings JL, Goldman DP, Simmons‐Stern NR, Ponton E. The costs of developing treatments for alzheimer's disease: A retrospective exploration. Alzheimer's & Dementia. 2021;18(3):469-477. doi:10.1002/alz.12450
13. Medicare coverage for alzheimer's and other Dementias. RetireGuide. https://www.retireguide.com/medicare/coverage/conditions-and-treatments/alzheimerdisease/. Accessed December 7, 2021.
14. Alzheimer's care costs far more than heart disease or cancer care. Fisher Center for Alzheimer's Research Foundation. https://www.alzinfo.org/articles/caregiving/alzheimers-care-costs-far-more-than-heart-disease-or-cancer-care/. Published December 15, 2015. Accessed May 24, 2022.
15. Costs of alzheimer's to Medicare and Medicaid. https://act.alz.org/site/DocServer/2012_Costs_Fact_Sheet_version_2.pdf?docID=7161. Accessed May 24, 2022.
16. Seven recent papers amplify advances in alzheimer's research. National Institute on Aging. https://www.nia.nih.gov/news/seven-recent-papers-amplify-advances-alzheimersresearch. Accessed November 30, 2021.
17. NIH invests in next iteration of public-private partnership to Advance Precision Medicine
Research for alzheimer's disease. National Institute on Aging.
https://www.nia.nih.gov/news/nih-invests-next-iteration-public-private-partnershipadvance-precision-medicine-research. Accessed November 30, 2021.
18. Commissioner of the FDA allows marketing of first direct-to-consumer tests that provide genetic risk information for certain conditions. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-allows-marketing-firstdirect-consumer-tests-provide-genetic-risk-information-certain-conditions. Accessed December 7, 2021.
19. The role of genes in your alzheimer's risk. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimersgenes/art-20046552. Published May 6, 2021. Accessed December 7, 2021.
20. CRISPR-Cas9: Introduction and discovery - youtube. https://www.youtube.com/watch?v=qc6xgb4VXl0. Accessed November 30, 2021.
21. Zhang X-H, Tee LY, Wang X-G, Huang Q-S, Yang S-H. Off-target effects in CRISPR/cas9-mediated genome engineering. Molecular Therapy - Nucleic Acids. 2015;4. doi:10.1038/mtna.2015.37
22. Full stack genome engineering. Synthego. https://www.synthego.com/blog/crispr-curediseases. Accessed November 30, 2021.
23. Van Beers BC. Rewriting the human genome, Rewriting Human Rights Law? human rights, human dignity, and human germline modification in the CRISPR era. Journal of Law and the Biosciences. 2020;7(1). doi:10.1093/jlb/lsaa006
24. Center for Drug Evaluation and Research. FDA's decision to approve new treatment for alzheimer's disease. U.S. Food and Drug Administration.
https://www.fda.gov/drugs/news-events-human-drugs/fdas-decision-approve-newtreatment-alzheimers-disease. Accessed December 7, 2021.
25. Schulman KA, Greicius MD, Richman B. Will CMS find aducanumab reasonable and necessary for alzheimer disease after FDA approval? JAMA. 2021;326(5):383. doi:10.1001/jama.2021.11768
26. Cook E. FDA's approval of Biogen's new alzheimer's drug has huge cost implications for
Medicare and beneficiaries. Medicare Report.
https://medicarereport.org/index.php/2021/06/11/fdas-approval-of-biogens-newalzheimers-drug-has-huge-cost-implications-for-medicare-and-beneficiaries/. Published June 11, 2021. Accessed December 1, 2021.
27. Sachs RE, Bagley N. Medicare coverage of aducanumab — implications for state budgets. New England Journal of Medicine. 2021;385(22):2019-2021. doi:10.1056/nejmp2115297
28. M M, JL F, KM G, et al. In phase 2, Donanemab curbs cognitive decline in early alzheimer's. ALZFORUM. https://www.alzforum.org/news/research-news/phase-2donanemab-curbs-cognitive-decline-early-alzheimers. Accessed December 1, 2021.
29. What new alzheimer's treatments are on the horizon? Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/in-depth/alzheimerstreatments/art-20047780. Published June 30, 2021. Accessed December 1, 2021.
